Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

Christina M. Marra, Yu Zhao, David B. Clifford, Scott Letendre, Scott Evans, Katherine Henry, Ronald J. Ellis, Benigno Rodriguez, Robert W. Coombs, Giovanni Schifitto, Justin C. McArthur, Kevin Robertson

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE:: To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition. DESIGN:: Multisite longitudinal observational study. SETTING:: Research clinics. STUDY PARTICIPANTS:: One hundred and one individuals with advanced HIV beginning or changing a new potent antiretroviral regimen were enrolled in the study. Data for 79 participants were analyzed. Participants underwent structured history and neurological examination, venipuncture, lumbar puncture, and neuropsychological tests at entry, 24, and 52 weeks. INTERVENTION:: Antiretroviral regimens were categorized as CNS penetration effectiveness (CPE) rank of at least 2 or less than 2. Generalized estimating equations were used to examine associations over the course of the study. MAIN OUTCOME MEASURES:: Concentration of HIV RNA in CSF and blood and neuropsychological test scores (NPZ4 and NPZ8). RESULTS:: Odds of suppression of CSF HIV RNA were higher when CPE rank was at least 2 than when it was less than 2. Odds of suppression of plasma HIV RNA were not associated with CPE rank. Among participants with impaired neuropsychological performance at entry, those prescribed regimens with a CPE rank of at least 2 or more antiretrovirals had lower composite NPZ4 scores over the course of the study. CONCLUSION:: Antiretroviral regimens with good CNS penetration, as assessed by CPE rank, are more effective in controlling CSF (and presumably CNS) viral replication than regimens with poorer penetration. In this study, antiretrovirals with good CNS penetration were associated with poorer neurocognitive performance. A larger controlled trial is required before any conclusions regarding the influence of specific antiretrovirals on neurocognitive performance should be made.

Original languageEnglish (US)
Pages (from-to)1359-1366
Number of pages8
JournalAIDS
Volume23
Issue number11
DOIs
StatePublished - Jul 2009

Keywords

  • Antiretroviral therapy
  • Cerebrospinal fluid
  • Cognition
  • HIV
  • Neuropsychological tests

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance'. Together they form a unique fingerprint.

Cite this